Published peptide research references
Vosoritide
Governed registry record
4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Approved source records
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
DOI: 10.1016/s0140-6736(20)31541-5
Source identity and connection checked by Codex (AI).
Real-world outcomes of vosoritide in achondroplasia: A systematic review and meta-analysis of multinational clinical evidence.
DOI: 10.1016/j.gim.2025.101670
Source identity and connection checked by Codex (AI).
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
DOI: 10.1038/s41436-021-01287-7
Source identity and connection checked by Codex (AI).
Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence.
Source identity and connection checked by Codex (AI).
Legacy research context
Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.
Researchers represented
- Savarirayan R
- Tofts L
- Irving M
- Wilcox W
- Bacino CA
- Hoover-Fong J
- Ullot Font R
- Harmatz P
- Rutsch F
- Bober MB
- Polgreen LE
- Ginebreda I
- Mohnike K
- Charrow J
- Hoernschemeyer D
- Ozono K
- Alanay Y
- Arundel P
- Kagami S
- Yasui N
- White KK
- Saal HM
- Leiva-Gea A
- Luna-González F
- Mochizuki H
- Basel D
- Porco DM
- Jayaram K
- Fisheleva E
- Huntsman-Labed A
- Day J
- Wilcox WR
- Font RU
- Kotani Y
- Day JRS
- Albuquerque ALB
- Dacoregio MI
- Rodrigues CG
- Bertola DR
- Zattar Ribeiro PV
- Jones HL
- Nania TI
- Moore JM
- Reed JD
- Lyons AW
- Potter P
- Ashurst J
- Holley H